Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers
Home › MD › BALTIMORE › JOHNS HOPKINS BAYVIEW MEDICAL CENTER INC

JOHNS HOPKINS BAYVIEW MEDICAL CENTER INC

NPI: 1790700904 · BALTIMORE, MD 21224 · General Acute Care Hospital

$9.20M
Total Medicaid Paid
329,591
Total Claims
232,271
Beneficiaries
173
Codes Billed
2018-01
First Month
2024-12
Last Month

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 75,957 $2.46M
2019 56,348 $1.05M
2020 29,298 $1.02M
2021 42,251 $1.25M
2022 48,789 $1.31M
2023 44,979 $1.19M
2024 31,969 $916K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99285 5,802 5,055 $1.65M
90834 20,149 11,191 $1.19M
G0463 Hospital outpatient clinic visit for assessment and management of a patient 54,524 43,345 $1.18M
90837 8,793 4,688 $837K
99284 4,037 3,425 $737K
G0378 Hospital observation service, per hour 1,240 1,054 $608K
90832 6,293 4,926 $321K
99283 2,481 2,126 $244K
97110 4,819 1,634 $233K
99212 1,078 633 $214K
96413 1,476 1,034 $213K
93306 919 872 $165K
80053 16,358 12,528 $164K
99211 1,829 1,201 $147K
94010 529 465 $108K
99281 3,376 2,398 $86K
74177 1,519 1,419 $76K
20610 1,443 1,191 $73K
71046 2,989 2,630 $55K
88305 1,284 1,128 $52K
97161 478 412 $49K
80048 5,099 3,394 $43K
85025 16,203 12,375 $43K
71260 638 595 $42K
95810 72 66 $40K
43239 109 102 $40K
71250 626 565 $35K
92134 814 749 $34K
72125 1,113 1,005 $34K
95811 25 12 $33K
70450 2,512 2,261 $32K
96372 1,785 1,429 $29K
80307 2,381 2,146 $20K
71045 1,931 1,742 $18K
99282 231 212 $17K
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) 4,136 2,499 $16K
94640 366 185 $16K
71275 146 118 $16K
36415 8,092 6,505 $16K
93922 66 63 $13K
97530 587 318 $13K
J3490 Unclassified drugs 2,718 1,635 $12K
87086 1,460 1,275 $12K
82962 6,184 2,969 $11K
97162 80 65 $11K
81001 4,480 3,827 $10K
87631 504 438 $10K
73560 401 359 $10K
73030 149 120 $9K
90715 287 229 $8K
84484 6,538 4,242 $8K
87389 617 529 $7K
90853 1,173 363 $7K
94060 21 12 $7K
87070 69 48 $7K
85027 3,086 2,471 $6K
86850 1,098 847 $5K
93971 43 39 $5K
73502 17 12 $4K
83036 2,900 2,786 $4K
J2704 Injection, propofol, 10 mg 3,655 2,737 $4K
80069 112 45 $4K
A9270 Non-covered item or service 32,466 8,479 $4K
J7120 Ringers lactate infusion, up to 1000 cc 4,449 3,357 $4K
80061 1,498 1,451 $4K
G2067 Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program) 24 15 $3K
85610 3,504 2,919 $3K
73110 38 25 $3K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 1,528 1,356 $3K
73630 125 106 $3K
J7030 Infusion, normal saline solution , 1000 cc 3,569 2,379 $3K
97140 627 223 $3K
87077 105 78 $3K
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg 3,572 3,064 $3K
86140 1,160 1,046 $3K
82803 855 614 $2K
90686 622 571 $2K
73610 85 78 $2K
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg 1,237 1,141 $2K
74176 48 41 $2K
90677 29 29 $2K
85018 138 115 $2K
92557 12 12 $2K
90662 637 587 $2K
96365 85 49 $1K
97116 147 37 $1K
94727 397 374 $1K
C1769 Guide wire 213 206 $1K
82306 524 498 $1K
G0108 Diabetes outpatient self-management training services, individual, per 30 minutes 13 12 $1K
J2270 Injection, morphine sulfate, up to 10 mg 648 463 $1K
73130 32 28 $1K
94729 628 599 $1K
97165 37 37 $1K
J0690 Injection, cefazolin sodium, 500 mg 1,083 865 $1K
G8987 Self care functional limitation, current status, at therapy episode outset and at reporting intervals 61 45 $1K
92083 13 12 $999.60
83605 1,989 1,474 $927.53
G8978 Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals 413 342 $845.07
81002 260 181 $812.94
82728 151 143 $725.79
J1644 Injection, heparin sodium, per 1000 units 1,167 706 $720.33
83880 2,672 2,054 $677.94
J1885 Injection, ketorolac tromethamine, per 15 mg 1,173 905 $670.37
97112 49 24 $667.79
96375 33 25 $662.40
J2405 Injection, ondansetron hydrochloride, per 1 mg 2,805 2,129 $626.67
J3010 Injection, fentanyl citrate, 0.1 mg 2,541 2,028 $610.90
87637 1,016 945 $605.67
J3535 Drug administered through a metered dose inhaler 27 24 $489.38
86900 873 731 $481.10
83735 4,834 3,526 $437.42
J1815 Injection, insulin, per 5 units 340 154 $428.21
87502 14 14 $425.55
84439 702 628 $424.23
J2370 Injection, phenylephrine hcl, up to 1 ml 177 156 $408.19
84443 2,434 2,293 $313.10
J2250 Injection, midazolam hydrochloride, per 1 mg 1,772 1,564 $295.64
83690 1,879 1,707 $294.82
J2710 Injection, neostigmine methylsulfate, up to 0.5 mg 16 14 $273.66
J3475 Injection, magnesium sulfate, per 500 mg 38 28 $247.12
J1170 Injection, hydromorphone, up to 4 mg 202 145 $198.15
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen 606 451 $173.58
70486 13 12 $166.49
84703 96 89 $166.43
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1,780 1,499 $160.51
84702 330 308 $156.82
86901 872 731 $151.76
82330 67 63 $141.15
Q0163 Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen 1,214 782 $129.58
85730 1,315 1,180 $127.83
J0696 Injection, ceftriaxone sodium, per 250 mg 126 94 $121.36
84132 1,239 1,151 $117.35
J1100 Injection, dexamethasone sodium phosphate, 1 mg 941 715 $101.57
82947 69 67 $96.76
85651 526 502 $94.88
82607 26 26 $93.48
82077 213 196 $88.66
J1200 Injection, diphenhydramine hcl, up to 50 mg 509 354 $84.21
J2060 Injection, lorazepam, 2 mg 109 70 $78.69
82043 228 227 $76.66
J2765 Injection, metoclopramide hcl, up to 10 mg 110 94 $74.43
97535 18 12 $67.29
87635 507 479 $64.27
82565 302 288 $60.39
82150 57 52 $56.78
83540 288 275 $38.49
87491 27 26 $38.29
84466 314 300 $31.87
81025 14 13 $28.17
J7512 Prednisone, immediate release or delayed release, oral, 1 mg 74 58 $25.93
87591 25 24 $19.15
J7050 Infusion, normal saline solution, 250 cc 517 425 $5.14
84100 457 341 $4.07
84295 115 112 $3.71
82435 25 25 $3.71
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg 14 12 $0.65
J0665 Injection, bupivicaine, not otherwise specified, 0.5 mg 252 230 $0.47
G8979 Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting 350 317 $0.04
G8990 Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals 15 12 $0.01
G8991 Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting 15 12 $0.01
G1012 Clinical decision support mechanism agilemd, as defined by the medicare appropriate use criteria program 2,385 1,549 $0.00
82948 179 108 $0.00
83970 69 67 $0.00
90656 35 35 $0.00
85652 384 361 $0.00
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 697 604 $0.00
85379 216 212 $0.00
J0131 Injection, acetaminophen, not otherwise specified,10 mg 13 12 $0.00
G8988 Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting 28 28 $0.00
96415 27 25 $0.00
J2371 Injection, phenylephrine hydrochloride, 20 micrograms 35 29 $0.00
J2003 Injection, lidocaine hydrochloride, 1 mg 22 22 $0.00